DAWN

NEUTRALM&A

Day One Biopharmaceuticals, Inc

2026-04-22

Price

$21.53

+0.19%

Score11.2Top Tier

Signals7/8 DNA0/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.7xvs 20d avg

Analysis

Day One Biopharmaceuticals (DAWN) is currently pinned near $21.53 following the recent announcement that Servier will acquire the company for $21.50 per share in a $2.5 billion all-cash deal. This definitive M&A catalyst perfectly explains the technical landscape, notably the initial SURGE to the deal price and the subsequent QUIET_STORM (1.5% realized volatility) as merger arbitrageurs step in to lock the spread. The broader RISK_ON macro regime and flush liquidity environment provided a highly conducive backdrop for biotech M&A, confirming this as a High-Conviction Price Discovery event that has now transitioned into a pure merger arbitrage play.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACK

Key Takeaways

Servier is acquiring DAWN for $21.50 per share in cash, representing a total equity value of $2.5 billion to acquire its pediatric glioma drug Ojemda.
The stock's technical profile (0.0% off highs, ultra-low 1.5% volatility) is entirely dictated by merger arbitrage pinning the stock to the acquisition price.
With the stock trading pennies above the $21.50 deal price, the market is pricing in a successful Q2 2026 close with a marginal possibility of a competing bid.

← Back to 2026-04-22 View Full DAWN History →Yahoo Finance &nearr;